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ABSTRACT: O-GlcNAc transferase (OGT) is a serine/
threonine glycosyltransferase that is essential for develop-
ment and continues to be critically important throughout
life. Understanding OGT’s complex biology requires
identifying its substrates. Here we demonstrate the utility
of a microarray approach for discovering novel OGT
substrates. We also report a rapid method to validate OGT
substrates that combines in vitro transcription-translation
with O-GlcNAc mass tagging. Among the validated new
OGT targets is Orthodenticle homeobox 2 (OTX2), a
transcription factor critical for brain development, which is
primarily expressed only during early embryogenesis and
in medulloblastomas, where it functions as an oncogene.
We show that endogenous OTX2 from a medulloblastoma
cell line is O-GlcNAcylated at several sites. Our results
demonstrate that protein microarray technology, com-
bined with the target validation strategy we report, is useful
for identifying biologically important OGT substrates,
including substrates not present in most tissue types or cell
lines.
P
rotein post-translational modiﬁcations (PTMs) are crucial
for the proper metabolic control of protein activity. One of
the most common PTMs in eukaryotes is O-GlcNAcylation, the
attachment of N-acetyl glucosamine (GlcNAc) to serine and
threonine side chains of intracellular proteins. This modiﬁca-
tion is eﬀected by O-GlcNAc transferase (OGT), an enzyme
essential for development that has been implicated in a variety
of diﬀerent signaling pathways.
1 OGT targets include kinases,
phosphatases, transcription factors, and metabolic enzymes, and
OGT has been implicated in insulin signaling, stress response
pathways, and cell-cycle regulation, among other processes.
Dysregulated O-GlcNAcylation has been linked to cancer,
diabetic complications, and other pathologies.
2 Deconvoluting
OGT’s myriad functions requires identifying its cellular
substrates and considerable eﬀort has been devoted to this
endeavor. The vast majority of known substrates were
identiﬁed using proteomic approaches based on liquid
chromatography tandem mass spectrometry (LC-MS/MS).
These methods require that O-GlcNAcylated cellular proteins
be enriched from the general protein population prior to LC-
MS/MS analysis.
3 A number of enrichment approaches have
been developed based on lectin aﬃnity capture or bioorthog-
onal labeling with biotin followed by streptavidin aﬃnity
capture.
4 While proteomic approaches are powerful, they have
limitations. Enrichment methods can isolate proteins that are
not O-GlcNAcylated as well as ones that are, resulting in false
positives, and some low abundance OGT substrates may still be
missed. Furthermore, O-GlcNAcylated proteins expressed only
during development or in specialized cell types will not be
identiﬁed in standard cell lines.
Human protein microarrays can circumvent common pitfalls
of methods that rely on substrate enrichment from complex
mixtures. Thousands of puriﬁed human proteins, including rare
and disease-relevant proteins, are present in known, roughly
equivalent concentrations on these arrays with their identities
spatially encoded.
5 Large microarrays have been used to
identify substrates for phosphorylation, acetylation and
ubiquitylation, but have not been applied to O-GlcNAcylation.
6
Here we demonstrate the utility of large microarrays for
discovering novel OGT substrates. Among a dozen new
substrates conﬁrmed using an eﬃcient, orthogonal validation
method is OTX2, a master regulator of neural development and
a known oncogene for medulloblastoma, the most common
malignant brain tumor in children.
7
Human OGT contains a C-terminal catalytic domain fused
to an N-terminal tetratricopeptide repeat (TPR) domain, which
is involved in protein−protein interactions.
8 OGT is expressed
as three diﬀerent isoforms that contain identical catalytic
domains but diﬀerent numbers of TPRs: nucleocytoplasmic
OGT (ncOGT) contains 12.5 TPRs, mitochondrially targeted
OGT (mOGT) contains 9.5 TPRs, and short OGT (sOGT)
contains 2.5 TPRs.
9 We puriﬁed each isoform from a bacterial
overexpression system and tested them for glycosylation of
protein substrates in HeLa cell extracts.
10 ncOGT and mOGT,
but not sOGT, showed robust glycosylation activity in these
extracts (Figure S1), consistent with previous reports.
9
Therefore, we used ncOGT and mOGT to probe a
commercially available microarray containing ∼8000 unique
human proteins. Microarrays were incubated with 40 μM UDP-
GlcNAc and 3 μM puriﬁed ncOGT or mOGT at room
temperature for one hour, and O-GlcNAc-modiﬁed proteins
were then detected using a monoclonal anti-O-GlcNAc primary
antibody (CTD110.6, Sigma) and a ﬂuorescent secondary
antibody (anti-mouse IgG, Alexa-ﬂuor 646 conjugate, Cellsig-
nal) (Figure 1a).
11 Because the anti-O-GlcNAc antibody
CTD110.6 can react with pre-existing O-GlcNAc residues on
the arrayed proteins, and has also been shown to bind to both
O- and N-linked glycans,
12 we incubated a control microarray
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Terms of Usewith UDP-GlcNAc, but without exogenous OGT, and
subsequently treated it with the antibodies. The signal
intensities from this control array were subtracted from the
data for the test arrays to ensure that any observed signal
increase in the test arrays was due to glycosylation by
exogenously added OGT. The top 2% of normalized signal
intensities for each OGT isoform, encompassing a total of 230
proteins, were identiﬁed as possible targets of OGT (Figure
1b). This is a stringent cutoﬀ and there are likely many other
OGT targets in the array, our ﬁrst goal was not to
comprehensively assess all substrates, but to establish whether
a microarray approach would be useful for identifying new
substrates. Among the 230 proteins were several known targets
of human OGT, including IRS1 and AKT1, which are involved
in insulin signaling, CRTC2, a central regulator of gluconeo-
genic gene expression, and CKII, a well-studied kinase involved
in numerous cellular processes.
13 However, the majority of the
top hits were not previously identiﬁed human OGT targets.
Ingenuity Pathway Analysis showed that the hits fall into several
functional classes, with the major categories including kinases,
transcription factors and apoptosis-related proteins (Table S3).
Validation is a major bottleneck for all OGT substrate
discovery eﬀorts. Putative OGT substrates identiﬁed by
proteomic methods are typically validated by transfecting
mammalian cell lines with an overexpression vector, immuno-
precipitating the expressed protein with a speciﬁc antibody, and
immunoblotting for the O-GlcNAc modiﬁcation using an anti-
O-GlcNAc antibody.
6b Alternatively, chemoenzymatic methods
can be used to install a biotin handle on all O-GlcNAcylated
proteins in a cell lysate, and speciﬁc proteins of interest can be
identiﬁed after streptavidin immunoprecipitation by Western
blotting using protein-speciﬁc antibodies.
14 These approaches
work, but are time-intensive, and screening multiple targets
requires a collection of protein-speciﬁc antibodies or
mammalian overexpression vectors. To accelerate substrate
validation, we developed an approach based on a method used
to conﬁrm ubiquitylation substrates.
15 In this approach, a
radiolabeled protein is expressed in vitro from a commercially
available cDNA clone and the O-GlcNAc post-translational
modiﬁcation is then detected following gel electrophoresis
(Figure 2a). Unlike ubiquitylation, O-GlcNAc modiﬁcations are
usually not detectable by mass shifts unless many sites are
modiﬁed. Therefore, we employed a mass-tagging strategy to
overcome this limitation.
16 Candidate proteins were expressed
from their respective cDNA clones in an in vitro transcription/
translation system (IVT, TnT SP6, Promega) supplemented
with 35S-methionine (35S-Met), which radiolabels the expressed
protein. Reactions were then incubated with OGT and a UDP-
GlcNAc analogue containing an N-acyl azide (UDP-GlcNAz;
Figure 2),
17 followed by azadibenzocyclooctyne-PEG, which
adds a 5 kDa tag to each GlcNAz.
18 Prior to using the method
to validate new substrates, we conﬁrmed that OGT eﬃciently
transfers GlcNAz to IVT-expressed nucleoporin62 (Nup62), a
well-characterized OGT target that has ten glycosylation sites
and thus undergoes a signiﬁcant mass shift even without a PEG
tag (Figure S2).
19 We then veriﬁed the mass-tagging method
using IVT-expressed Nup62 and CRTC2, which also has
multiple O-GlcNAcylation sites (Figure S3).
13c For both
proteins, gel analysis of IVT reactions showed a single band
that shifted to a set of higher molecular weight bands only in
reactions containing OGT as well as UDP-GlcNAz and
azadibenzocyclooctyne-PEG. Twenty IVT-expressed proteins
were then analyzed using the method outlined in Figure 2a, and
12 of these were mass shifted, conﬁrming the microarray
identiﬁcation of them as substrates (Figure 2, Table S4, Figure
Figure 1. Known and novel OGT targets can be identiﬁed on
microarrays. (a) Schematic of the microarray approach. A ﬂuorescent
antibody reports on O-GlcNAcylated proteins. (b) Normalized signal
intensities plotted against Array ID. Selected known (red) and novel
(blue) targets are indicated. Complete list of 230 targets can be found
in Tables S1 and S2.
Figure 2. A rapid, orthogonal validation method conﬁrms new OGT
substrates. (a) Schematic of the validation method. (b) Radiolabeled
HGS, E2F8, and OTX2 bands shift to higher molecular weight bands.
Nine other OGT substrates were validated (Figure S4 and Table S4).
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conﬁrm for technical reasons; i.e., the IVT-expressed protein is
not correctly folded or is not identical to the form on the
microarray, which was expressed in cells and may contain other
PTMs. To distinguish between these possibilities, other
validation methods can be used.
6b Nevertheless, the conﬁrmed
substrates highlight the utility of the approach. The IVT, OGT,
and mass-tagging reactions can be accomplished in under four
hours, making it possible to validate a large number of possible
substrates in a day once in vitro expression from a commercially
available cDNA clone has been veriﬁed. This validation
procedure should be generally useful for conﬁrming new
OGT substrates. Several of t h et w e l v ev a l i d a t e dO G T
substrates are involved in gene transcription,
20 including
SSBP2, SSBP3, the glucocorticoid receptor, MEF2A, E2F8,
and OTX2. Some of these proteins showed a single 5 kDa shift,
consistent with one glycosylation event per protein (HGS,
Figure 2b), while others showed multiple bands, indicating
several O-GlcNAc modiﬁcations per protein (OTX2 and E2F8,
Figure 2b).
21
OTX2, a previously unknown OGT substrate, is a tran-
scription factor that acts as a master regulator of brain
development.
7 Although otx2 expression is switched oﬀ in most
tissues after early embryogenesis, it is highly expressed in ∼75%
of medulloblastomas, responsible for the majority of fatal
childhood brain cancers.
22 Along with c-Myc, OTX2 has been
identiﬁed as an important oncogene in these tumors.
23 After
verifying that OTX2 is expressed in the medulloblastoma cell
line D283 Med (Figure S5), we adapted a previously developed
mass-tagging approach to assess its endogenous O-GlcNAcy-
lation status (Figure 3a).
21 In the adaptation of this approach, a
β-1,4-galactosyltransferase variant, GalTY289, is used to transfer
azido-GalNAc (GalNAz) to existing O-GlcNAcs on proteins
obtained from a cell lysate. Lysates are then treated with
ADIBO-PEG to install a mass tag on each GalNAz. Following
SDS-PAGE of total cell lysate, proteins of interest are detected
by immunoblotting. SP1, a ubiquitous human transcription
factor known to be highly O-GlcNAcylated,
24 shifted to higher
molecular weight upon mass-tagging while actin, which is not
O-GlcNAcylated, did not. As with SP1, the OTX2 bands shifted
to higher molecular weight (Figure 3a), conﬁrming that this
protein is O-GlcNAcylated. Several shifted bands were
observed, implying that OTX2 from medulloblastoma cells is
O-GlcNAcylated at multiple sites, as it is when expressed via
IVT (Figure 2b). We conﬁrmed this ﬁnding by treating D283
Med cells with 50 μM Ac-5S-GlcNAc, which is metabolized to
the validated OGT inhibitor UDP-5S-GlcNAc.
25 Using anti-
Nup62 and anti-OTX2 antibodies, we found that inhibitor
treatment resulted in a detectable shift to lower molecular
weight for both proteins, consistent with the loss of multiple O-
GlcNAc modiﬁcations due to OGT inhibition (Figure 3b). The
roles of O-GlcNAc modiﬁcation in the oncogenic functions of
OTX2 are under investigation.
We have shown that human protein microarrays can detect
novel OGT substrates. We note that antibody bias and
subtraction of the control array mean that we are not detecting
all of the O-GlcNAcylated substrates on the array. The
development of alternative detection methods should overcome
this limitation. While these microarrays do not yet contain all
human proteins, they contain many thousands, including
substrates of low abundance, temporally limited expression or
glycosylation patterns, or highly restricted cell type speciﬁcity.
Hence, microarray substrate proﬁling, combined with the IVT
validation method described, can powerfully complement
existing proteomic approaches. Moreover, microarray methods
are uniquely well suited to exploring the eﬀects of changes in
OGT structure on substrate selection.
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